TG THERAPEUTICS, INC. (TGTX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | 141,148 | 83,879 | 73,466 | |
| Other selling, general and administrative | 43,541 | 33,221 | 31,828 | |
| Noncash compensation | 12,044 | 8,745 | 6,962 | |
| Total selling, general and administrative | 55,585 | 41,966 | 38,790 | |
| Other research and development | 27,464 | 17,110 | 15,036 | |
| Noncash compensation | 4,318 | 3,028 | 2,520 | |
| Total research and development | 31,782 | 20,138 | 17,556 | |
| Cost of revenue | 18,938 | 9,341 | 8,304 | |
| Total costs and expenses | 106,305 | - | - | |
| Operating income (loss) | 34,843 | 12,434 | 8,816 | |
| Other income | 2,793 | 2,666 | 1,712 | |
| Interest expense | 6,716 | 10,832 | 3,977 | |
| Total other expense, net | -3,923 | -8,166 | -2,265 | |
| Net income (loss) before taxes | 30,920 | 4,268 | 6,551 | |
| Income tax benefit (expense) | 2,733 | 388 | -328 | |
| Net income (loss) | 28,187 | 3,880 | 6,879 | |
| Basic (in dollars per share) | 0.19 | 0.03 | 0.05 | |
| Diluted (in dollars per share) | 0.17 | 0.02 | 0.04 | |
| Us-gaap_weightedaveragenumberofdilutedsharesoutstanding | 162,559,404 | 160,714,388 | 159,423,571 | |
| Weighted-average common shares outstanding (in shares) | 146,739,833 | 145,102,479 | 144,727,482 | |